BW710

BW710 is an orally active fibroblast growth factor receptor 2 (FGFR2) inhibitor. BW710 inhibits the proliferation of BaF3-FGFR2 cells with an IC50 of 2.8 nM. BW710 abolishes FGFR2 enzymatic activity and is selective against other 75 tyrosine kinases including FGFR1, FGFR3, and FGFR4 at 1 μM. BW710 suppresses the FGFR2 signaling and selectively inhibits FGFR2-driven cancer cell proliferation. BW710 displays reasonable pharmacokinetic properties with an oral bioavailability of 29 % in mice[1].

Product Specifications

UNSPSC

12352005

Target

FGFR

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

NC(N=CN=C12)=C2C(C3=CC=C(S4(CCCCCN=4)=O)C=C3)=C(N1C)C(C=C5)=C(F)C=C5NC(C(C)=C)=O

Molecular Formula

C28H29FN6O2S

Molecular Weight

532.63

References & Citations

[1]Yang B, et al. Discovery of BW710 as a potent, selective and orally bioavailable fibroblast growth factor receptor 2 (FGFR2) inhibitor. Eur J Med Chem. 2025 Apr 5;287:117339.